Cristina Fevola

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies.

Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies.

Journal: Human vaccines & immunotherapeutics

Published: June 29, 2026

Real-life effectiveness and safety of lumacaftor/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre study.

Real-life effectiveness and safety of lumacaftor/ivacaftor in preschool children with cystic fibrosis: data from an italian multicentre study.

Journal: Pediatric research

Published: December 03, 2025

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: September 30, 2025

Prevalence and risk factors for recurrent Staphylococcus aureus small-colony variants in people with cystic fibrosis followed at the Tuscan Regional Reference Center.

Prevalence and risk factors for recurrent Staphylococcus aureus small-colony variants in people with cystic fibrosis followed at the Tuscan Regional Reference Center.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: June 03, 2025

Raised Intracranial Pressure in Children Treated With Elexacaftor/Tezacaftor/Ivacaftor: Need for Surveillance.

Raised Intracranial Pressure in Children Treated With Elexacaftor/Tezacaftor/Ivacaftor: Need for Surveillance.

Journal: Clinical therapeutics

Published: May 22, 2025

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

Journal: British journal of pharmacology

Published: March 14, 2025

Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels.

Monitoring early antibiotic treatment with anti-Pseudomonas aeruginosa serology: a comparison of two specific antibody panels.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: March 13, 2025

Corrigendum to "Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers" [Journal of Cystic Fibrosis xxx (2025) 1-10].

Corrigendum to "Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers" [Journal of Cystic Fibrosis xxx (2025) 1-10].

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: March 01, 2025

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Journal: Scientific reports

Published: February 24, 2025

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.

Journal: Therapeutic advances in respiratory disease

Published: February 11, 2025

Nocardia Isolation in People with Cystic Fibrosis and Non-CF Bronchiectasis: A Multicenter Italian Study.

Nocardia Isolation in People with Cystic Fibrosis and Non-CF Bronchiectasis: A Multicenter Italian Study.

Journal: Antibiotics (Basel, Switzerland)

Published: January 26, 2025

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Journal: Journal of clinical medicine

Published: November 27, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026